Effects of Somatostatin and Indomethacin Mono or Combination Therapy on High-risk Hyperamylasemia and Post-pancreatitis Endoscopic Retrograde Cholangiopancreatography Patients: A Randomized Study

What Was Tested

The paper reports a study of Somatostatin, published as a randomized controlled trial.

Endoscopic retrograde cholangiopancreatography (ERCP) is a minimally invasive technique widely used to diagnose and treat pancreatic and biliary diseases; however, it is linked with imminent hyperamylasemia and post-ERCP pancreatitis (PEP).

Who Took Part

The study group was 1458 patients.

Altogether 1458 patients who underwent ERCP in their hospital from January 2016 to May 2022 were included in this investigation and categorized into 4 groups based on the treatment regimen: placebo, indomethacin, somatostatin, and indomethacin + somatostatin.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Because people in this Somatostatin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some patients received a placebo instead of Somatostatin, giving a reference point.

The pre operation and post operation (at 6, 12, and 24 h) hospitalization cost, length of stay, the occurrence of hyperamylasemia and PEP, levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), IL-8, and VAS pain score were determined in the 4 groups.

The somatostatin and the indomethacin + somatostatin groups indicated markedly alleviated hospitalization fee, length of stay, the occurrence of hyperamylasemia and PEP, VAS, and the levels of IL-6, TNF-α, and IL-8 at 6, 12, and 24 h post operation compared with the placebo cohort.

It is also worth noting that the side effects of both drugs are rare and mild.

What Was Measured

The subject headings attached to it are Cholangiopancreatography, Endoscopic Retrograde, Indomethacin, Hyperamylasemia, Risk Factors, Tumor Necrosis Factor-alpha, Interleukin-6 and Interleukin-8.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Somatostatin in 1458 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (Surgical laparoscopy, endoscopy & percutaneous techniques), a journal based in United States.

More context: the Somatostatin compound page, all human trials.